The Endocannabinoid System in Ageing: A New Target for Drug Development

Author(s): A. Paradisi, S. Oddi, Maccarrone

Journal Name: Current Drug Targets

Volume 7 , Issue 11 , 2006

Become EABM
Become Reviewer
Call for Editor


Endocannabinoids are a new class of lipids, which include amides, esters and ethers of long chain polyunsaturated fatty acids. Anandamide (N-arachidonoylethanolamine; AEA) and 2-arachidonoylglycerol are the main endogenous agonists of cannabinoid receptors able to mimic several pharmacological effects of Δ9-tetrahydrocannabinol, the active principle of Cannabis sativa preparations like hashish and marijuana. AEA is released “on demand” from membrane lipids, and its activity at the receptors is limited by cellular uptake followed by intracellular hydrolysis. Together with AEA and congeners, the proteins which bind, synthesize, transport and hydrolyze AEA form the “endocannabinoid system”. Endogenous cannabinoids are present in the central nervous system and in peripheral tissues, suggesting a physiological role as broad spectrum modulators. This review summarizes the main features of the endocannabinoid system, and the latest advances on its involvement in ageing of central and peripheral cells. In addition, the therapeutic potential of recently developed drugs able to modulate the endocannabinoid tone for the treatment of ageing and age-related human pathologies will be reviewed.

Keywords: ageing, cannabinoids, nervous system, immune system, inflammation, excitotoxicity, osteoarthritis, neurodegenerative disorders

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [1539 - 1552]
Pages: 14
DOI: 10.2174/1389450110607011539
Price: $65

Article Metrics

PDF: 16